Definitive Contract 75A50123C00039

This is a $749,000.00 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to In Diagnostics, Inc. to develop endpoint and kinetic measurement capabilities on a low-cost, disposable spectrophotometer platform. The contract does not have a set-aside designation and is scheduled for completion by June 30, 2025. The awardee, In Diagnostics, Inc., is a for-profit organization located in Carlsbad, California.

This is a $749,999.01 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Red Queen Therapeutics Inc., a self-certified small disadvantaged business. The contract is for research and development of a rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections. This contract is not set aside and has an ultimate completion date of...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Revvity Health Sciences, Inc. (doing business as PerkinElmer Inc.) for $86,241.80. The contract is for the provision of PerkinElmer branded reagents and kits to support NIAID's Vaccine Research Center (VRC) and its work on therapeutic and vaccine candidates for diseases including COVID-19, HIV, influenza, malaria, and Ebola. The contract is not set aside...

This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures. The contract is for the development of medical countermeasures that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The...

This is a definitive, cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Public Health Vaccines LLC, a for-profit limited liability company. The purpose of this $101,433,355.76 contract modification is to exercise and fully fund Option 4/CLIN 0005 for the advanced research and development of an RVSV-MARV vaccine. The contract has an ultimate completion date of December 31, 2028 and was originally awarded on...

This contract was awarded by the Centers for Disease Control and Prevention (CDC) to Meridian Life Science Inc., a small disadvantaged business, to develop scalable inactivation capabilities. The firm-fixed price purchase order, valued at $149,748.00, was awarded on September 1, 2016, with a completion date of March 31, 2017. The contract did not have a set-aside designation. Without additional information on the original solicitation, the specific products or services to be delivered under this...

This is a firm fixed-price definitive contract awarded by the Office of the Assistant Administrator, a civilian agency, to Domestic Awardees (Undisclosed), a for-profit organization doing business as Federal Egov IAE Initiative - Generic Entity Identifier. The contract, worth $135,869.13, is for the delivery of an Infectious Disease Project Manager. There is no set-aside designation for this award. The contract has a period of performance through September 11, 2024. Domestic Awardees is an...

This is a $330,136,249.00 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to 4J Therapeutics Inc. to demonstrate the versatility and efficacy of their programmable antiviral technology platform. The purpose is to assemble a preclinical package for LNA14 and perform a Phase 1a study in healthy adults. The contract is not set aside and is the result of a Broad Agency Announcement (BAA) solicitation issued by the Biomedical Advanced...

This is a $1,303,426.92 firm-fixed-price purchase order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc., a small business biotechnology company. The contract is for sorting peripheral blood mononuclear cells from Lassa fever virus survivors to discover and produce monoclonal antibodies for assessment in in vitro and in vivo assays. The original solicitation was issued as a Request for Proposal (RFP) under NAICS code 541380, with a small business size standard of $19.0 million....

This is a $65,867,803.99 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to VIR Biotechnology, Inc., a self-certified small disadvantaged business. The contract is for the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. This contract was awarded under a Broad...